心脏手术后白蛋白使用情况
该回顾性单中心队列研究纳入心脏手术后入住心胸ICU的成人患者,比较4%人白蛋白暴露与未暴露者的结局和费用。研究期间3656例接受心脏手术,排除后2594例纳入分析。校正后医院死亡率无显著差异(OR 1.24;95%CI 0.56-2.79;P=0.6)。白蛋白暴露者因出血和/或填塞返回手术室更多(6.1% vs 2.1%;OR 2.84;95%CI 1.81-4.45;P<0.01),接受浓缩红细胞输注更多(P<0.001),ICU和医院住院时间更长(平均差18小时;95%CI 10.3-25.6;P<0.001和87.5小时;95%CI 40.5-134.6;P<0.001),费用更高(ICU费用平均差2728美元;95%CI 1566-3890;医院费用平均差5427美元;95%CI 3294-7560)。
要点
- 心脏手术后ICU使用4%人白蛋白者医院死亡率校正后无显著增加(OR 1.24;95%CI 0.56-2.79;P=0.6)。
- 白蛋白暴露者因出血和/或填塞返回手术室的比例更高(6.1% vs 2.1%;OR 2.84;95%CI 1.81-4.45;P<0.01)。
- 白蛋白暴露者接受浓缩红细胞输注更多(P<0.001)。
- 白蛋白暴露者ICU住院时间平均延长18小时(95%CI 10.3-25.6;P<0.001),医院住院时间平均延长87.5小时(95%CI 40.5-134.6;P<0.001)。
- 白蛋白暴露者ICU费用平均增加2728美元(95%CI 1566-3890),医院费用平均增加5427美元(95%CI 3294-7560)。
适用人群与场景
- 心脏手术后入住心胸ICU的成人患者。
研究设计与关键结果
- 研究设计为回顾性单中心队列研究,含经济评估,在澳大利亚的心胸ICU进行。
- 白蛋白暴露与未暴露相比,校正后医院死亡率无显著差异(OR 1.24;95%CI 0.56-2.79;P=0.6)。
- 白蛋白暴露者因出血和/或填塞返回手术室的比例为6.1%,未暴露者为2.1%(OR 2.84;95%CI 1.81-4.45;P<0.01)。
- 白蛋白暴露者接受浓缩红细胞输注更多(P<0.001)。
- 白蛋白暴露者ICU住院时间平均延长18小时(95%CI 10.3-25.6;P<0.001),医院住院时间平均延长87.5小时(95%CI 40.5-134.6;P<0.001)。
- 白蛋白暴露者ICU费用平均增加2728美元(95%CI 1566-3890),医院费用平均增加5427美元(95%CI 3294-7560)。
证据类型、等级与局限
- 证据类型:回顾性单中心队列研究(含经济评估)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为心脏手术后暴露于白蛋白的患者死亡率未增加,但暴露者病情严重度更高、并发症更多、医疗费用更高。
- 作者指出需要随机对照试验来确定白蛋白在该场景中是否有效和安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 2 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the effect of albumin exposure in ICU after cardiac surgery on hospital mortality, complications, and costs.
DESIGN: A retrospective, single-center cohort study with economic evaluation.
SETTING: Cardiothoracic ICU in Australia.
PATIENTS: Adult patients admitted to the ICU after cardiac surgery.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Comparison of outcomes and costs in ICU after cardiac surgery based on 4% human albumin exposure. During the study period, 3,656 patients underwent cardiac surgery. After exclusions, 2,594 patients were suitable for analysis. One-thousand two-hundred sixty-four (48.7%) were exposed to albumin and 19 (1.4%) of those died. The adjusted hospital mortality of albumin exposure compared with no albumin was not significant (odds ratio, 1.24; 95% CI, 0.56-2.79; p = 0.6). More patients exposed to albumin returned to the operating theater for bleeding and/or tamponade (6.1% vs 2.1%; odds ratio, 2.84; 95% CI, 1.81-4.45; p < 0.01) and received packed red cell transfusions (p < 0.001). ICU and hospital lengths of stay were prolonged in those exposed to albumin (mean difference, 18 hr; 95% CI, 10.3-25.6; p < 0.001 and 87.5 hr; 95% CI, 40.5-134.6; p < 0.001). Costs (U.S. dollar) were higher in patients exposed to albumin, compared with those with no albumin exposure (mean difference in ICU costs, $2,728; 95% CI, $1,566-3,890 and mean difference in hospital costs, $5,427; 95% CI, $3,294-7,560).
CONCLUSIONS: There is no increased mortality in patients who are exposed to albumin after cardiac surgery. The patients exposed to albumin had higher illness severity, suffered more complications, and incurred higher healthcare costs. A randomized controlled trial is required to determine whether albumin use is effective and safe in this setting.
参考来源
- Matebele MP, Ramanan M, Thompson K, et al. Albumin Use After Cardiac Surgery. Crit Care Explor. 2020. PMID: 32766560. doi:10.1097/CCE.0000000000000164
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。